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Introduction. In patients receiving cardiac resynchronization therapy (CRT), failure rate to 
implant the left ventricular (LV) lead by the traditional trans-venous approach is 4-8%. Surgical 
epicardial implantation is considered as an alternative, but this technique is not without morbidity. 
Evidence from case documentation and from small trial batches demonstrated the viability of 
endocardial LV lead implantation where surgical epicardial lead placement is not applicable. 
Material and Methods. Four patients were implanted with endocardial LV lead using the 
transseptal atrial approach after unsuccessful transvenous implantation. Implantation of an 
endocardial active fixation LV leads was successful in all patients with stable electrical parameters 
immediately after implantation and over the follow-up period. All patients received anticoagulation 
therapy in order to target the international normalized ratio of 2.5-3.5 and have not experienced any 
thromboembolic, hemorrhagic events, or infection. 
Results. Follow-up echocardiography indicated significant improvement of LV systolic function 
(24 + 4.9 to 32 + 5.1 %, P = 0.023) with a notable improvement of the functional status.  
Conclusions. Endocardial left ventricular lead implantation can be a valuable and safe 
alternative technique to enable LV stimulation in high surgical risk patients where standard coronary 
sinus implant is unsuccessful. 
Key words: biventricular pacing, transseptal lead, transseptal pacing, endocardial stimulation, 
cardiac resynchronization therapy.  
INTRODUCTION 
Cardiac resynchronization therapy (CRT), 
with atrio-biventricular pacing has been a tremendous 
advance in the treatment of symptomatic congestive 
heart failure patients presenting with severely 
impaired left ventricular function associated with 
ventricular dyssynchrony and intraventricular con-
duction disturbances [1-3]. The standard approach 
indicates the necessity for the implantation of an 
LV pacing lead transvenously into one of the tributary 
veins of the coronary sinus (CS). However, even 
with the improvement in dedicated devices and 
increased operator experience, failure to implant a 
CS lead has been reported in 4-8% of the cases  
[4, 5]. Unfavorable CS or vein anatomy, such as 
CS dissection, occlusion, or abnormal ostium of the 
CS or focal coronary vein stenosis are the most 
frequent reasons. Post-implant dislocation of the lead, 
high pacing threshold or phrenic nerve stimulation 
also diminishes the effectiveness of LV stimulation 
[6-8]. In cases of unsuccessful LV lead placement 
through the CS, surgical epicardial lead implantation 
via a lateral thoracotomy or minimal-invasive 
thoracoscopy is considered the standard alternative 
method that requires general anesthesia [9-11]. In 
patients with advanced heart failure, this approach 
may be linked with a high morbidity and mortality. 
Endocardial LV lead placement through an atrial 
transseptal approach has been described previously 
as an alternative technique to provide CRT in cases 
where epicardial LV lead implantation is contra-
indicated or is at increased risk [12-18]. In the 
following paper we describe the technique that we 
used and the outcomes of the transseptal endocardial 
LV implant in patients for whom transvenous CS 
lead placement had failed and are not eligible for 
surgical epicardial implantation and have no 
contraindication for lifelong oral anticoagulation. 
Patients 
From October 2014 to October 2015, at the 
Electrophysiology and PM department of Semmel-
weis University Heart Center, four patients (3 males; 
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mean age 62.5 years) had undergone endocardial 
LV lead implantation where LV pacing could not 
be achieved via the coronary sinus despite the 
application of interventional techniques including 
venoplasty. Patients had New York Heart Association 
III to IV symptoms and had compelling indication 
for life long systemic anticoagulation. All patients 
had left bundle branch block (LBBB). Pre-implant-
ation echocardiography revealed severely depressed 
LV function. Patient’s characteristic features are 
listed in Table 1. Surgical lead implantation was 
contraindicated in three patients because of a very 
high anesthetic and surgical risk. Patient 2 did not 
sign the consent for epicardial surgical LV lead 
implantation. In patients 1, 3 and 4, the CRT 
devices together with the right atrial and ventricular 
lead were implanted in the first procedure having 
the port of the LV lead sealed with an IS-1 plug. 
The transseptal LV lead implantation was performed 
on a later procedure. In patient 2 the transseptal LV 
lead implantation was implanted during the first 
procedure.  
Table 1 
Characteristic features of patients 
      
Pt no. Age Gender Etiology of cardiomyopathy 
NYHA 
Functional 
Class 
QRS 
(ms) 
LVEF 
(%) 
Follow-
up 
months 
MR grade before 
implantation (I-IV) 
ACT before 
implantation 
1 60 M Ischemic III 186 28 11 III Yes (for AF) 
2 45 M non-ischemic Iva 193 21 10 III Yes (IVT) 
3 70 M non-ischemic III-IV 205 27 7 III-IV Yes (for AF) 
4 75 F Ischemic III 210 24 6 III Yes (for AF) 
Pt, patient, NYHA, New York Heart Association Functional Class, LV, Left Ventricular, LVEF, Left Ventricular Ejection Fraction, MR, Mitral, regurgitation, 
ACT, Anticoagulation Therapy, IVT, Interventricular Thrombosis, AF, Atrial fibrillation 
 
MATERIAL AND METHODS 
The placement of the LV endocardial lead 
was done via a combined femoral and subclavian 
approach. The implantation starts with a standard 
transseptal puncture from the right femoral vein. 
The puncture was performed with the guidance of 
fluoroscopy and with continuous monitoring of the 
arterial pressure. Following the successful trans-
septal puncture, confirmed by the left atrial 
pressure curve, 5000 IU of intravenous heparin was 
administered. A guide wire (0.035 inch × 260 cm) 
was advanced into one of the pulmonary veins and 
the dilator was removed and the sheath was with-
drawn into the right atrium (Figure 1). An angioplasty 
balloon (8 mm × 40 mm Fox Plus Abbott Vascular) 
was positioned across the septal puncture site and 
was inflated using contrast agent. In a CS guiding 
sheath a steerable electrophysiological catheter is 
advanced from the left subclavian area towards the 
septum of the right atrium. The balloon was deflated 
then it was withdrawn into the transseptal sheath 
and the guide wire was maintained in the left 
atrium (Figure 2). The steerable catheter is pushed 
on transseptally into the left atrium and then to the 
left ventricle. Maintaining the electrophysiological 
catheter in position the guiding sheath is advanced 
to the left atrium. In cases where the sheath did not 
advance through the site of the puncture, the angio-
plasty balloon was again placed at the puncture site 
and it was inflated and deflated as per the need 
(Figure 3). When we identified the optimal pacing 
site, the electrophysiological catheter was with-
drawn into the sheath and the sheath was pushed 
against the LV wall to ensure stable position. 
Subsequently, a standard active fixation bipolar 
lead was screwed into the desired location of the 
postero-lateral area of the left ventricle (Figure 4). 
After measuring the pacing and sensing thresholds, 
the guiding sheath had been removed using a longitu-
dinal slitter tool. Maintaining a sufficient slack in 
the lead, the proximal end was secured in the pre-
pectoral region and connected to the CRT device.In 
all patients, the atrial lead has been implanted in 
the right atrial appendage and the right ventricular 
lead was placed in the right ventricular septum.  
 
Figure 1. A guide wire in the Left Atrium  
after successful transseptal puncture. 
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Figure 2 A. Balloon dilatation of the trans- 
septal puncture site. 
 
Figure 2B. Advancement of the EP catheter  
to the right atrium. 
 
Figure 2C. The balloon is deflated and withdrawn  
into the right atrium. 
 
Figure 3A. The EP catheter is advanced trans- 
septally into the left atrium. 
 
Figure 3B. The EP catheter and the sheath are advanced  
into the left ventricle. 
 
 
Figure 4A. The active fixation lead is screwed  
in the left ventricle. 
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Figure 4B. Final lead position. 
RESULTS 
All patients had successfully been implanted 
with LV endocardial leads. Three of our patients 
 
received CRT-D devices, while one patient received a 
CRT-pacemaker. A sum-up of the device implantation 
and follow-up parameters is available in Table 2. 
There was no phrenic nerve stimulation observed at 
stimulation with 10 V, 0.4 msec. During the follow-up 
period, no lead dysfunction or dislocation was 
observed. All patients have been on long-term anti-
coagulation and the international normalized ratio 
was maintained between 2.5 and 3.5. There were 
no hematoma or serious post-procedural bleeding 
observed due to the use of full anticoagulation 
during the procedure. None of the patients developed 
any thromboembolic events on last follow-up. All 
patients had improvement in the functional status 
thus symptoms had ameliorated at least one NYHA 
class. There was a significant improvement in the 
left ventricular systolic function, from a mean LV 
ejection fraction of 24 + 4.9 to 32 + 5.1 % (p = 
0.023). We did not observe significant changes in 
the grade of mitral regurgitation throughout the 
follow-up period (p = 0.18).  
Table 2 
Implant and Follow-up data of the patients 
Pt 1 2 3 4 
Device 
Incepta Boston Scientific, CRT-D 
Miami, USA 
Incepta Boston Scientific, CRT-D 
Miami, USA 
Entovis, HF-T, CRT-P, 
BiotronikGmbH&Co, Berlin, Germany 
Protecta XT, CRT-D, Medtronic;  
Minnesota, USA 
LV lead Medtronic 5076-65cm  Medtronic 5076-65cm  Medtronic 5076-65cm  Medtronic 5076-65cm  
Success Yes Yes Yes Yes 
  
R wave 
(mV) 
Threshold 
(Volts/ms) 
Impedance 
(Ohms) 
R wave 
(mV) 
Threshold 
(Volts/ms) 
Impedance 
(Ohms) 
R wave 
(mV) 
Threshold 
(Volts/ms) 
Impedance 
(Ohms) 
R wave 
(mV) 
Threshold 
(Volts/ms) 
Impedance 
(Ohms) 
Implant  8.5 0.6/0.4 495 15.5 0.7/0.4 754 20 0.8/0.4 678 7.2 0.75/0.4 754 
1 Week postimplant 9.1 0.7/0.4 537 14.7 0.7/0.4 461 21 0.9/0.4 658 7.4 1/0.4 713 
3 months postimplant 9 0.7/0.4 430 15 0.7/0.4 490 20 0.8/0.4 589 7.3 0.75/0.4 710 
6 months postimplant 9.3 0.7/0.4 483 15.3 0.7/0.4 710 22 0.8/0.4 630 7.2 0.75/0.4 720 
Complications None none none none 
Follow-up NYHA 
Class II II-III II II 
LVEF at follow-up 38% 29% 35% 27% 
Grade of MR at 
follow-up III II-III III III 
Thromboembolism  None none none none 
Pt, patient, NYHA, New York Heart Association Functional Class, LV, Left Ventricular, LVEF, Left Ventricular Ejection Fraction, MR, Mitral regurgitation 
 
DISCUSSION 
For patients in whom transvenous left ventricular 
lead placement in the tributary veins of the CS is 
unsuccessful and are ineligible for surgical epicardial 
implantation, transseptal endocardial LV lead im-
plantation is an alternative method for providing 
resynchronization therapy. Evidence from case 
documentation and from small trial batches proved 
the safety and feasibility of this alternative technique. 
In 1998 Jaïs et al. described the first successful 
implant of endocardial LV lead using a combined 
approach with a transseptal puncture from the 
femoral vein and a snare technique through the 
right jugular vein [12]. Since then, Leclercq et al. 
have described several cases of successful LV lead 
implantation using a direct transseptal approach via 
the right internal jugular vein [14]. Another group 
has described a method using direct TS puncture 
from the left axillary vein [18]. In 2007 Van Gelder 
et al. and Nuta et al. described successful endocardial 
LV lead placement from the subclavian vein into 
the LV cavity via the interatrial septum, following 
transseptal puncture through the femoral vein to 
allow entry of the LV lead from above [15, 16]. In 
our patients, we used the latter approach.  
One of the advantages of this interventional 
alternative technique is that there is no need for 
general anesthesia and there is minimum post-
operative recovery. In comparison to epicardial 
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pacing, endocardial LV stimulation has some 
potential advantages. The transseptal access allows 
a broader choice for the pacing site inside the LV 
cavity and is not limited by the anatomy of the 
tributary veins of the CS. In case of a high pacing 
threshold, the lead can be repositioned to a different 
site inside the LV cavity, this is often difficult 
when maneuvering the lead in the cardiac venous 
system. The risk for phrenic nerve stimulation is 
low. In our small study population no phrenic nerve 
stimulation occurred at high energy stimulation and 
optimal implantation and follow-up electrical para-
meters were observed (Table 2). Experimental and 
clinical observations also indicated that LV endo-
cardial stimulation enables a more physiological 
electrical activation of the left ventricle, with a 
transmural activation spreading from the endocardium 
to the epicardium [19, 20]. Better hemodynamic 
results with higher aortic and mitral time velocity 
integral, improvement of LV fractional shortening 
and less ventricular dyssynchrony were reported 
with endocardial than with epicardial LV stimulation 
[21, 22]. During follow-up in our patients, we 
observed that the totally endocardial pacing was 
correlated with a marked improvement of the LV 
systolic function and improvement in the functional 
status of the patients. 
The disadvantages of this alternative technique 
include the risk associated with the transseptal 
catheterization, the unknown long-term thrombo-
embolic risk, the need for lifetime anticoagulation, 
risks associated with position of the lead across the 
mitral valve, and the need of complex procedures 
to manage device related infections. The transseptal 
approach via the interatrial septum has been used 
for various interventional and electrophysiological 
procedures. Therefore, without any doubt, experienced 
operators have less risk with this procedure. The 
use of intraoperative anticoagulation and the need 
of anticoagulation right after the implantation lead 
to the increase of the risk of periprocedural 
bleeding complications. In our small study cohort 
there has not been any complications related to the 
procedure nor major hematoma was observed. The 
main concern is regarding the long-term risks of 
thromboembolic complications associated with 
endocardial LV stimulation. It is mandatory to use 
 
anticoagulant therapy in these patients and the 
recommended target INR is between 2.5 and 3.5 
[23, 24]. However, the use of anticoagulation is 
common in the majority of these patients due to the 
presence of atrial fibrillation. In all of our patients 
there was an indication for the use anticoagulant 
therapy, before the implantation of a transseptal 
system – three patients for paroxysmal atrial 
fibrillation and one for intraventricular thrombosis. 
Long-term follow-up data of the thromboembolic 
complications in patients who had a transseptal 
endocardial LV lead implanted are scarce. So far 
no thromboembolic complications where reported 
as long as anticoagulant therapy was followed [13, 
25-27]. During follow-up no thromboembolic 
events occurred in our study population. In patients 
with transseptal CRT with an endocardial LV lead 
crossing the interatrial septum and the mitral valve, 
there is a theoretically increased risk of worsening 
the mitral regurgitation and of mitral valve endo-
carditis. No significant increase in the grade of 
mitral regurgitation has been reported with LV 
endocardial pacing [13-16, 26, 28]. We did not 
document any significant deterioration of mitral 
regurgitation in our study patients. To date there is 
no record of more frequent endocarditis associated 
with this technique. Throughout the follow-up period 
we did not have any lead infection.  
CONCLUSIONS 
Transseptalendocardial left ventricular lead 
implantation appears to be a valuable and safe 
second alternative with the benefit of an endo-
cardial pacing site. The disadvantages of this 
technique are the need for permanent anti-
coagulation and the lead interaction with the mitral 
valve, though any significant complications as a 
result of this phenomena have not been reported 
until now. Nevertheless, more data is required to 
evaluate the safety and long-term efficacy of this 
alternative technique. 
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Introducere. Implantarea clasică prin abord epicardic transvenos a electrodului 
de ventricul stâng (VS) pentru a realiza terapia de resincronizare cardiacă (TRC) 
nu este posibilă în 4-8% din cazuri. La acei pacienţi, la care plasarea epicardică 
chirurgicală a electrodului de stimulare al VS nu este posibilă datorită unui risc 
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anestezico-chirurgical inacceptabil, implantarea endocardică a electrodului de 
stimulare al VS poate fi o alternative viabilă.  
Metode. S-a efectuat TRC în cazul a patru pacienţi, cu plasarea endocardică 
prin abord transseptal atrial a sondei de VS, după ce implantarea prin abord 
epicardic transvenos a fost lipsită de succes. La toţi pacienţii s-a realizat poziţionarea 
cu succes a unui electrod de stimulare cu fixare activă la nivelul endocardului VS, 
cu parametrii electrici stabili la momentul implantului şi pe perioada de urmărire. 
Toţi pacienţii au primit tratament anticoagulant oral cu o ţintă a INR de 2,5-3,5. 
Pe perioada de urmărire nu am observant complicaţii tromboembolice, hemo-
ragice sau infecţioase.  
Rezultate. Toţi pacienţii au avut un răspuns clinic şi structural adecvat cu 
ameliorarea semnificativă a funcţiei sistolice a VS (24 + 4,9 to 32 + 5.1 % P = 
0.023) şi a statusului funcţional.  
Concluzii. Plasarea endocardică prin abord transseptal atrial a electrodului 
de stimulare al VS, poate fi o tehnică intervenţională alternativă, sigură şi valoroasă 
la acei pacienţi la care riscul anestezico-chirurgical este ridicat şi poziţionarea 
clasică prin abord transvenos al electrodului de stimulare al VS nu este posibilă. 
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